Protocol Ledger

NCT06581432 · Phase II · RECRUITING

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Interventional Phase II clinical trial protocol NCT06581432 sponsored by Boehringer Ingelheim in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-11 Enrollment: 588 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06581432
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)588 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06581432
Protocol FieldVerified Registry Value
NCT IdentifierNCT06581432
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment588 participants (ESTIMATED)
Registered Start Date2024-10-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI